|
1
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WEE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gandhi L, Rodríguez-Abreu D, Gadgeel S,
Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ,
Powell SF, et al KEYNOTE-189 Investigators, : Pembrolizumab plus
chemotherapy in metastatic non-small-cell lung cancer. N Engl J
Med. 378:2078–2092. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Paz-Ares L, Luft A, Vicente D, Tafreshi A,
Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, et
al KEYNOTE-407 Investigators, : Pembrolizumab plus chemotherapy for
squamous non-small-cell lung cancer. N Engl J Med. 379:2040–2051.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Socinski MA, Jotte RM, Cappuzzo F, Orlandi
F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D,
Thomas CA, Barlesi F, et al IMpower150 Study Group, : Atezolizumab
for first-line treatment of metastatic nonsquamous NSCLC. N Engl J
Med. 378:2288–2301. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Herbst RS, Soria J-C, Kowanetz M, Fine GD,
Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger
SN, et al: Predictive correlates of response to the anti-PD-L1
antibody MPDL3280A in cancer patients. Nature. 515:563–567. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rizvi NA, Hellmann MD, Snyder A, Kvistborg
P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al: Cancer
immunology. Mutational landscape determines sensitivity to PD-1
blockade in non-small cell lung cancer. Science. 348:124–128. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tumeh PC, Harview CL, Yearley JH, Shintaku
IP, Taylor EJM, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu
V, et al: PD-1 blockade induces responses by inhibiting adaptive
immune resistance. Nature. 515:568–571. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ready N, Hellmann MD, Awad MM, Otterson
GA, Gutierrez M, Gainor JF, Borghaei H, Jolivet J, Horn L, Mates M,
et al: First-line nivolumab plus ipilimumab in advanced
non-small-cell lung cancer (CheckMate 568): Outcomes by programmed
death ligand 1 and tumor mutational burden as biomarkers. J Clin
Oncol. 37:992–1000. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Blank C, Kuball J, Voelkl S, Wiendl H,
Becker B, Walter B, Majdic O, Gajewski TF, Theobald M, Andreesen R,
et al: Blockade of PD-L1 (B7-H1) augments human tumor-specific T
cell responses in vitro. Int J Cancer. 119:317–327. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bremnes RM, Busund L-T, Kilvær TL,
Andersen S, Richardsen E, Paulsen EE, Hald S, Khanehkenari MR,
Cooper WA, Kao SC, et al: The role of tumor-infiltrating
lymphocytes in development, progression, and prognosis of non-small
cell lung cancer. J Thorac Oncol. 11:789–800. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Spranger S, Bao R and Gajewski TF:
Melanoma-intrinsic β-catenin signalling prevents anti-tumour
immunity. Nature. 523:231–235. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Spranger S, Dai D, Horton B and Gajewski
TF: Tumor-residing Batf3 dendritic cells are required for effector
t cell trafficking and adoptive t cell therapy. Cancer Cell.
31:711–723.e4. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rijsewijk F, van Deemter L, Wagenaar E,
Sonnenberg A and Nusse R: Transfection of the int-1 mammary
oncogene in cuboidal RAC mammary cell line results in morphological
transformation and tumorigenicity. EMBO J. 6:127–131. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yook JI, Li XY, Ota I, Fearon ER and Weiss
SJ: Wnt-dependent regulation of the E-cadherin repressor snail. J
Biol Chem. 280:11740–11748. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim Y, Jin D, Lee BB, Cho EY, Han J, Shim
YM, Kim HK and Kim DH: Overexpression of β-catenin and cyclin D1 is
associated with poor overall survival in patients with stage IA-IIA
squamous cell lung cancer irrespective of adjuvant chemotherapy. J
Thorac Oncol. 11:2193–2201. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang H, Zhang G, Zhang H, Zhang F, Zhou B,
Ning F, Wang HS, Cai SH and Du J: Acquisition of
epithelial-mesenchymal transition phenotype and cancer stem
cell-like properties in cisplatin-resistant lung cancer cells
through AKT/β-catenin/Snail signaling pathway. Eur J Pharmacol.
723:156–166. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yoo SB, Kim YJ, Kim H, Jin Y, Sun P-L,
Jheon S, Lee JS and Chung JH: Alteration of the
E-cadherin/β-catenin complex predicts poor response to epidermal
growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)
treatment. Ann Surg Oncol. 20 (Suppl 3):S545–S552. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ye L, Li H, Wang H, Liu H, Lv T, Zhang F
and Song Y: Abnormal β-catenin expression and reduced
tumor-infiltrating T cells are related to poor progression in
non-small cell lung cancer. Int J Clin Exp Pathol. 10:11572–11579.
2017.PubMed/NCBI
|
|
20
|
Hogg N, Takacs L, Palmer DG, Selvendran Y
and Allen C: The p150,95 molecule is a marker of human mononuclear
phagocytes: Comparison with expression of class II molecules. Eur J
Immunol. 16:240–248. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hume DA: Macrophages as APC and the
dendritic cell myth. J Immunol. 181:5829–5835. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Malhotra V, Hogg N and Sim RB: Ligand
binding by the p150,95 antigen of U937 monocytic cells: Properties
in common with complement receptor type 3 (CR3). Eur J Immunol.
16:1117–1123. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Diamond MS, Garcia-Aguilar J, Bickford JK,
Corbi AL and Springer TA: The I domain is a major recognition site
on the leukocyte integrin Mac-1 (CD11b/CD18) for four distinct
adhesion ligands. J Cell Biol. 120:1031–1043. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Blackford J, Reid HW, Pappin DJC, Bowers
FS and Wilkinson JM: A monoclonal antibody, 3/22, to rabbit CD11c
which induces homotypic T cell aggregation: Evidence that ICAM-1 is
a ligand for CD11c/CD18. Eur J Immunol. 26:525–531. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ihanus E, Uotila LM, Toivanen A, Varis M
and Gahmberg CG: Red-cell ICAM-4 is a ligand for the
monocyte/macrophage integrin CD11c/CD18: Characterization of the
binding sites on ICAM-4. Blood. 109:802–810. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ingalls RR and Golenbock DT: CD11c/CD18, a
transmembrane signaling receptor for lipopolysaccharide. J Exp Med.
181:1473–1479. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Myones BL, Dalzell JG, Hogg N and Ross GD:
Neutrophil and monocyte cell surface p150,95 has iC3b-receptor
(CR4) activity resembling CR3. J Clin Invest. 82:640–651. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Loike JD, Sodeik B, Cao L, Leucona S,
Weitz JI, Detmers PA, Wright SD and Silverstein SC: CD11c/CD18 on
neutrophils recognizes a domain at the N terminus of the A alpha
chain of fibrinogen. Proc Natl Acad Sci USA. 88:1044–1048. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Garnotel R, Rittié L, Poitevin S,
Monboisse J-C, Nguyen P, Potron G, Maquart F-X, Randoux A and
Gillery P: Human blood monocytes interact with type I collagen
through alpha × beta 2 integrin (CD11c-CD18, gp150-95). J Immunol.
164:5928–5934. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Goldstraw P, Crowley J, Chansky K, Giroux
DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V and Sobin L;
International Association for the Study of Lung Cancer
International Staging Committee; Participating Institutions, : The
IASLC Lung Cancer Staging Project: Proposals for the revision of
the TNM stage groupings in the forthcoming (seventh) edition of the
TNM Classification of malignant tumours. J Thorac Oncol. 2:706–714.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Schalper KA, Brown J, Carvajal-Hausdorf D,
McLaughlin J, Velcheti V, Syrigos KN, Herbst RS and Rimm DL:
Objective measurement and clinical significance of TILs in
non-small cell lung cancer. J Natl Cancer Inst. 107:dju4352015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Roach C, Zhang N, Corigliano E, Jansson M,
Toland G, Ponto G, Dolled-Filhart M, Emancipator K, Stanforth D and
Kulangara K: Development of a companion diagnostic PD-L1
immunohistochemistry assay for pembrolizumab therapy in
non-small-cell lung cancer. Appl Immunohistochem Mol Morphol.
24:392–397. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rizvi NA, Cho BC, Reinmuth N, Lee KH, Luft
A, Ahn MJ, van den Heuvel MM, Cobo M, Vicente D, Smolin A, et al
MYSTIC Investigators, : Durvalumab with or without tremelimumab vs
standard chemotherapy in first-line treatment of metastatic
non-small cell lung cancer: The MYSTIC Phase 3 randomized clinical
trial. JAMA Oncol. 6:661–674. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Schumacher TN and Schreiber RD:
Neoantigens in cancer immunotherapy. Science. 348:69–74. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zeng DQ, Yu YF, Ou QY, Li XY, Zhong RZ,
Xie CM and Hu QG: Prognostic and predictive value of
tumor-infiltrating lymphocytes for clinical therapeutic research in
patients with non-small cell lung cancer. Oncotarget.
7:13765–13781. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Naito Y, Saito K, Shiiba K, Ohuchi A,
Saigenji K, Nagura H and Ohtani H: CD8+ T cells
infiltrated within cancer cell nests as a prognostic factor in
human colorectal cancer. Cancer Res. 58:3491–3494. 1998.PubMed/NCBI
|
|
37
|
Spranger S and Gajewski TF:
Tumor-intrinsic oncogene pathways mediating immune avoidance.
OncoImmunology. 5:e10868622015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Galluzzi L, Chan TA, Kroemer G, Wolchok JD
and López-Soto A: The hallmarks of successful anticancer
immunotherapy. Sci Transl Med. 10:102018. View Article : Google Scholar
|
|
39
|
Garris CS, Arlauckas SP, Kohler RH, Trefny
MP, Garren S, Piot C, Engblom C, Pfirschke C, Siwicki M,
Gungabeesoon J, et al: Successful anti-PD-1 cancer immunotherapy
requires T cell-dendritic cell crosstalk involving the cytokines
IFN-gamma and IL-12. Immunity. 49:1148–1161.e7. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Galluzzi L, Spranger S, Fuchs E and
López-Soto A: WNT signaling in cancer immunosurveillance. Trends
Cell Biol. 29:44–65. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yaguchi T, Goto Y, Kido K, Mochimaru H,
Sakurai T, Tsukamoto N, Kudo-Saito C, Fujita T, Sumimoto H and
Kawakami Y: Immune suppression and resistance mediated by
constitutive activation of Wnt/β-catenin signaling in human
melanoma cells. J Immunol. 189:2110–2117. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Holtzhausen A, Zhao F, Evans KS, Tsutsui
M, Orabona C, Tyler DS and Hanks BA: Melanoma-derived Wnt5a
promotes local dendritic-cell expression of IDO and
immunotolerance: Opportunities for pharmacologic enhancement of
immunotherapy. Cancer Immunol Res. 3:1082–1095. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hasegawa T, Suzuki H, Yamaura T, Muto S,
Okabe N, Osugi J, Hoshino M, Higuchi M, Ise K and Gotoh M:
Prognostic value of peripheral and local forkhead box
P3+ regulatory T cells in patients with non-small-cell
lung cancer. Mol Clin Oncol. 2:685–694. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Muto S, Owada Y, Inoue T, Watanabe Y,
Yamaura T, Fukuhara M, Okabe N, Matsumura Y, Hasegawa T, Osugi J,
et al: Clinical significance of expanded Foxp3+
Helios− regulatory T cells in patients with non-small
cell lung cancer. Int J Oncol. 47:2082–2090. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sheridan C: Wnt is back in drugmakers'
sights, but is it druggable? Nat Biotechnol. 36:1028–1029. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Woo SR, Fuertes MB, Corrales L, Spranger
S, Furdyna MJ, Leung MY, Duggan R, Wang Y, Barber GN, Fitzgerald
KA, et al: STING-dependent cytosolic DNA sensing mediates innate
immune recognition of immunogenic tumors. Immunity. 41:830–842.
2014.Erratum in: Immunity 42: 199, 2015. View Article : Google Scholar : PubMed/NCBI
|
